The present study evaluated a novel investigational vitamin D repletion therapy : a modified-release ( MR ) formulation of calcifediol designed to raise serum 25-hydroxyvitamin D in a gradual manner to minimize the induction of CYP24 and , thereby , improve the SHPT control .